United States: Biosimilars In The Limelight – A Lot Has Happened Since January 2018

Last Updated: June 25 2018
Article by Joanne S. Hawana

A lot has happened since we last addressed new biosimilar developments in January 2018. In the intervening months, there have been many significant developments related to FDA's implementation of an efficient regulatory program for biosimilar products and the abbreviated BLA (aBLA) review process. Today we're going to recap some of what has transpired over the past 5 months in the biosimilars space in an attempt to get our readers caught up.

Two New Approvals

Two important biosimilar "firsts" have been achieved by the FDA and the respective product developers/aBLA sponsors. On May 15, FDA approved the first biosimilar of Epogen®/Procrit® (epoetin alfa) for the treatment of anemia caused by chronic kidney disease and chemotherapy – developed by Pfizer/Hospira and called Retacrit (epoetin alfa-epbx).  Then on June 4th, the Agency approved Mylan/Biocon's aBLA for Fulphila (pegfilgrastim-jmdb), the first biosimilar to Neulasta® (pegfilgrastim) to decrease the chance of infection in certain patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy.

This brings the total number of FDA-licensed biosimilars to 11 – although only 3 have been launched commercially due to ongoing patent litigation, settlements, and such. You can see an updated version of our Status of Biosimilars Chart here.

Interestingly, the aBLA for Fulphila (pegfilgrastim-jmdb) did not go through the advisory committee process like we has seen occur for every prior application for the first-to-be-reviewed biosimilar of a reference biosimilar product. It remains to be seen whether that administrative decision by the Agency was (a) due to its familiarity with the related molecule filgrastim – a biosimilar version was approved in 2015 as the first-ever aBLA, and several more filgrastim aBLAs are presently under review – (b) possibly related to the increased political pressure on FDA and other components with the Department of Health and Human Services (HHS) to deliver on President Trump's promise to tackle high drug prices, or (c) something else entirely. As of the date of this posting, no administrative records or review documents for the Fulphila aBLA have been released publicly.

Revised Guidance

Also on June 4, FDA issued a revised version of the draft guidance document Formal Meetings Between the FDA and Sponsors or Applicants of BsUFA Products. The revisions were made to take into account BsUFA II, enacted last year as part of the FDA Reauthorization Act, and the performance goals under the current iteration of the Biosimilar User Fee Program.

Monograph Developments

In March 2018, the CBER and CDER Directors jointly sent a letter to USP, the private standard-setting body, regarding USP's stated intent to create biological drug product monographs. In short, Dr. Peter Marks and Dr. Janet Woodcock expressed their concerns that the USP proposal, if implemented, could "delay or impede licensure of a biosimilar that meets the licensure requirements under section 351(k) of the [Public Health Service] Act" but that does not necessarily "match the standards in the USP monograph associated with the reference product."

USP initially responded to the concerns on April 2, 2018 by issuing a public statement that it "will not develop a new monograph for a biologic unless there is stakeholder consensus supporting its creation, including the support of FDA. USP's proposed revision is intended to align compendial names with FDA's biologics naming approach and avoid potential issues for manufacturers and other stakeholders." The Chief Operating Officer of USP, Dr. Ronald Piervincenzi, also responded directly to the FDA center directors in a letter dated April 27, 2018. It has been quite fascinating to watch the debate between two entities with such importance for drug and biologic developers take place so publicly over the past several months. Rest assured that the conversations regarding biological product standards are not over.

Final Thoughts

We'll close this by noting that biosimilars, as part of the FDA's overall Drug Competition Action Plan (see a prior post here), have continued to receive a lot of press attention but have had little substantive change to date. In conjunction with the announcement of the HHS Blueprint to Lower Drug Pricing to much fanfare on May 11, 2018 (see here), FDA Commissioner Gottlieb issued his own concurrent statement that focused on steps the Agency is taking to strengthen and advance the generic and biosimilar markets.

Dr. Gottlieb has been touting the "Biosimilar Action Plan" for several months now, so we expect to see some concrete actions soon under this so-called BAP. While the plan is expected to include changes in the proposed interchangeability standards that were issued as draft guidance in the waning days of the Obama Administration, we know little about the Agency's plans for other biosimilar-specific actions.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions